Veda Giri, MD

Veda Giri, MD

Contact Dr. Giri

1025 Walnut Street,
Suite 1015
Medical College Building
Philadelphia, PA 19107

(215) 503-5253
(215) 503-9506 fax

Most Recent Peer-reviewed Publications

  1. Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study
  2. Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017
  3. Exploring Asian Indian and Pakistani views about cancer and participation in cancer genetics research: toward the development of a community genetics intervention
  4. Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling
  5. The role of genetic counseling in familial and sporadic cancer: Considerations, challenges, and collaboration
  6. Prevalence and Characteristics of Patients with Suspected Inherited Renal Cell Cancer: Application of the ACMG/NSGC Genetic Referral Guidelines to Patient Cohorts
  7. Familial prostate cancer
  8. HOXB13 and other high penetrant genes for prostate cancer
  9. High prevalence of discordant human papillomavirus and p16 oropharyngeal squamous cell carcinomas in an African American cohort
  10. Lessons Learned from Implementing a Prostate Cancer Risk Assessment Program for Underserved High-Risk Men in the Community: the Prostate REACH Project
  11. How I Do It: Genetic counseling and genetic testing for inherited prostate cancer
  12. Interest in genomic SNP testing for prostate cancer risk: A pilot survey
  13. Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer
  14. Gene panel testing for inherited cancer risk
  15. Prostate cancer early detection, version 1.2014: Featured updates to the NCCN guidelines
  16. Prevalence of the HOXB13 G84E mutation among unaffected men with a family history of prostate cancer
  17. Validation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer
  18. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: Results from the initial screening round of the IMPACT study
  19. Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men
  20. Rates and predictors of colorectal cancer screening by race among motivated men participating in a prostate cancer risk assessment program